Could you provide some references to support your argument? Patent applications are not proper references.
Here are some to support mine.
With regard to the value of patents (and the dubious worth of patent applications), here's the Bioshares website. In particular, read 'Biotech checklist for investors.'
http://www.bioshares.com.au/investmentguide.htm
With regard to FDA.
The FDA classed APAS as Class II with special controls. On page 4, second last, of its Classicifation document, it says equivalent devices will need FDA clearance before marketing.
http://www.accessdata.fda.gov/cdrh_docs/pdf15/DEN150059.pdf
Why the hype?, page-94
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.001(6.25%) |
Mkt cap ! $23.30M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.6¢ | 1.5¢ | $8.549K | 565.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250000 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 188838 | 1 |
View Market Depth
| Last trade - 11.33am 09/07/2024 (20 minute delay) ? |
| LBT (ASX) Chart |